Cyclin D1 down-regulation is essential for DBC2's tumor suppressor function

Takashi Yoshihara1, Denise Collado, Masaaki Hamaguchi

  • 1Department of Biological Sciences, Fordham University, 441 E Fordham Road, Larkin Hall, Bronx, NY 10458, USA.

Insights

The tumor suppressor gene DBC2 inhibits breast cancer cell growth by reducing Cyclin D1 (CCND1) levels. Overexpressing CCND1 counteracts DBC2

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • DBC2 is a tumor suppressor gene implicated in breast cancer.
  • DBC2 regulates diverse cellular functions including cell cycle and apoptosis.
  • The precise mechanism of DBC2's tumor suppression is not fully understood.

Purpose of the Study:

  • To elucidate the mechanism by which DBC2 suppresses breast cancer proliferation.
  • To investigate the role of Cyclin D1 (CCND1) in DBC2-mediated tumor suppression.

Main Methods:

  • Investigated the effect of DBC2 expression on breast cancer cell proliferation.
  • Analyzed the expression levels of Cyclin D1 (CCND1) in response to DBC2.
  • Examined the impact of CCND1 overexpression on DBC2's growth-inhibitory effects.

Main Results:

  • DBC2 suppresses breast cancer cell proliferation by down-regulating Cyclin D1 (CCND1).
  • Constitutive overexpression of CCND1 abrogated the growth-suppressive effect of DBC2.
  • CCNE1 expression under a CCND1 promoter also conferred protection against DBC2.

Conclusions:

  • Down-regulation of CCND1 is a critical step in DBC2's tumor suppressor function in breast cancer cells.
  • This finding enhances the understanding of DBC2's role in cancer biology.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...